PD-L1抑制剂致1例免疫性肝炎病例分析及药学监护

Pharmaceutical Monitoring of Immunohepatitis Caused by PD-L1 Inhibitor:a Case Study

目的分析1例PD-L1抑制剂致免疫性肝炎不良反应,探讨临床药师在临床药学监护中的作用。方法临床药师对患者治疗方案提出药学建议,并开展药学监护。结合文献及相关指南等,进行病例分析。结果临床药师为患者提供有效的免疫相关性不良反应治疗管理方案。患者经激素和免疫抑制剂治疗后病情趋于好转。结论临床药师应关注PD-L1抑制剂使用中的免疫相关不良反应,协助医生保障患者临床用药安全。

Objective To explore the role of clinical pharmacists in the treatment of adverse drug reactions induced by PD-L1 inhibitors.Methods Related literature and guidelines were reviewed,while pharmaceutical recommendations and care were given by clinical pharmacists in response to adverse reactions induced after treatment of immune hepatitis with PD-L1 inhibitors(durvalumab).Results Adverse reactions were assessed by clinical pharmacists,who offered an effective and feasible treatment program so that the patient got better after treatment with hormones and immunosuppressive agents.Conclusion Clinical pharmacists should be alert to immune-related adverse reactions of PD-L1 inhibitors and help physicians to ensure the safety of clinical medication.